期刊文献+

非诺贝特纳米混悬剂的生物利用度研究 被引量:3

Preparation and bioavailability evaluation of fenofibrate nanosuspension
下载PDF
导出
摘要 目的:制备非诺贝特纳米混悬剂胶囊,分别在空腹和饱腹条件下,有大鼠灌胃非诺贝特纳纳米混悬剂,考察其体内吸收特性,并与市售微粉化非诺贝特胶囊进行对照,评价其相对生物利用度。方法:以高效液相色谱法测定大鼠灌胃给药前后的血药浓度。结果:与市售微粉化胶囊相比,在饱腹和空腹条件下,非诺贝特纳米混悬剂胶囊相对生物利用度分别达到136.45%和148.48%。结论:非诺贝特纳米混悬剂胶囊与市售微粉化胶囊相比,生物利用度较高。 Objective Fenofribate nanosuspension capsule was prepared.Fasted and fed rats were intragastrical administrate nanosuspension,respectively,studying the in vivo absorption and comparing commercially micronized fenofribate capsules,evaluated the relative bioavailability.Method The plasma concentrations in rats were measured by HPLC.Results In satiety and fasting conditions,the relative bioavailability has reached to 136.45% and 148.48% compared with the commercial capsule.Conclusion The bioavailability of fenofribate nanosuspension capsule enhances compared with the commercially micronized.
出处 《吉林医学》 CAS 2011年第19期3849-3851,共3页 Jilin Medical Journal
关键词 非诺贝特 纳米粒 纳米混悬剂 生物利用度 Fenofibrate Nanoparticles Nanosuspension Bioavailability
  • 相关文献

参考文献4

  • 1Balakumar P, Rohilla A, Mahadevan N. Pleiotropic actionsof fenofibrate on the heart [ J ]. Pharmacological Research,2011, 63(1) :8.
  • 2Cornelia MK, Rainer HM. Drug nanocrystals of poorly solu- ble drugs produced by high pressure homogenisatlon [ J ] . Eur J Pharm Biopharm,2006,62( 1 ) :3.
  • 3Ranjita Shegokar, Rainer H. Muller. Nanocrystals: Industri-ally feasible multifunctional formulation technology for poorly solu-ble actives [ J ]. International Journal of Pharmaceutics, 2010,399(1) :129.
  • 4张惠宏,胡富强,袁弘,方明.溶剂扩散法制备丙酸倍氯米松固体脂质纳米粒[J].药学学报,2003,38(4):302-306. 被引量:10

二级参考文献15

  • 1Müller RH, Mder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art [J]. Eur J Pharm Biopharm, 2000,50(1):161-177.
  • 2Yang SC, Zhu JB, Lu Y, et al. Body distribution of camptothecin solid lipid nanoparticles after oral administration [J]. Pharm Res, 1999,16(5):751-757.
  • 3Yang SC, Lu LF, Cai Y, et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain [J]. J Controlled Release, 1999,59(3):299-307.
  • 4Müller RH, Maaen S, Weyhers H, et al. Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN) [J]. Int J Pharm, 1996,138(1):85-94.
  • 5Müller RH, Lucks JS. Arzneistofftrger aus festen Lipidteilchen, Feste Lipidnanosphren (SLN) [P]. Eur Pat: 0605497,1993-03-25.
  • 6Maaβen S, Schwarz C, Mehnert, et al. Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles (SLN) [J]. Proc Int Symp Control Release Bioact Mater, 1993,20:490-491.
  • 7Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution [P]. US Pat: 5250236,1993-10-05.
  • 8Mühlen AZ, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism [J]. Eur J Pharm Biopharm, 1998,45(2):149-155.
  • 9Mühlen AZ, Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles [J]. Pharmazie, 1998,53(8):552-559.
  • 10Kawashima Y, Yamamoto H, Takeuchi H, et al. Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods [J]. Eur J Pharm Biopharm, 1998,45(1):41-48.

共引文献9

同被引文献33

  • 1邱枫,肇丽梅,何晓静,孙亚欣.人血浆中非诺贝特酸的测定及其药动学研究[J].华西药学杂志,2008,23(3):308-309. 被引量:2
  • 2徐帆,冯恩富,余昉.HPLC法测定血浆中非诺贝特活性代谢物非诺贝酸的浓度[J].中国药师,2007,10(6):530-532. 被引量:9
  • 3郑杨,张志丽,王立红,等.非诺贝特固体分散体制备工艺研究及比较[J].中国药剂学杂志,2012,10(2):26-34.
  • 4Dasandi B, Sanjay S, Shivprakash. Determination of fenofibric acid in human plasma by ultra performance liquid chromatography - electrospray ionization mass spectrometry:application to a bioequiv- alence study[ J]. Biomed Chromatogr,2009,23:922 -928.
  • 5Raymond R T, Effi S, Danang AY, et al. Bioequivalence study of two formulations Of bisoprolol fumarate film - coated tablets in healthy subjects [ J ]. Drug Design Development and Therapy, 2012,6:311 -316.
  • 6张俭俭,孙晓东.新型脂质体的应用研究进展[J].中国药房,2007,18(31):2465-2466. 被引量:7
  • 7Guay DR. Micronized fenofibrate: a new fibric acid hypolipidemic agent [J]. Ann Pharmacother, 1999, 33 (10) : 1083-1103.
  • 8Patel AR, Vavia PR. Preparation and in vivo evaluation of SMEDDS ( self-microemulsifying drug delivery system ) con- taining fenofibrate [J]. AAPS J, 2007, 9 ( 3 ) : 344-352.
  • 9Vogt M, Kunath K, Dressman JB. Dissolution enhance- ment of fenofibrate by micronization, cogrinding and spray- drying: comparison with commercial preparations [J]. Eur J PharmBiopharm, 2008, 68 (2) : 283-288.
  • 10Ehen YP, Lu Y, Chen JM, et al. Enhanced bioavailability of abe poorly water-soluble drug fenofibrate by using liposomes containing abile salt [J]. Int J Pharm, 2009, 376 ( 1-2 ) : 153-160.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部